Literature DB >> 25089373

Shortcomings of pertussis vaccines: why we need a third generation vaccine.

Jan T Poolman1.   

Abstract

First generation whole-cell (wP) and second generation acellular (aP) pertussis vaccines have been highly effective in preventing childhood deaths due to pertussis, yet both vaccines have drawbacks that have limited their long-term usefulness. These include issues of reactogenicity and potency in the case of wP, and limited durability of protection and the potential for selection of escape mutants in the case of aP. Neither vaccine prevents disease in neonatal infants who continue to die from pertussis. A third generation of pertussis vaccines that provides broad, durable protection is needed. In the meantime, countries using wP should continue to do so, while countries using aP need to consider policies and schedules that reduce pertussis transmission to unvaccinated infants. In this respect, maternal vaccination appears to be a promising solution.

Entities:  

Keywords:  Bordetella pertussis; efficacy; immunogenicity; pertactin; vaccine

Mesh:

Substances:

Year:  2014        PMID: 25089373     DOI: 10.1586/14760584.2014.944902

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  8 in total

Review 1.  Bordetella pertussis evolution in the (functional) genomics era.

Authors:  Thomas Belcher; Andrew Preston
Journal:  Pathog Dis       Date:  2015-08-21       Impact factor: 3.166

2.  The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development.

Authors:  Andrew Preston
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

3.  Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination.

Authors:  David J Dowling; Soumik Barman; Alyson J Smith; Francesco Borriello; Danielle Chaney; Spencer E Brightman; Gandolina Melhem; Byron Brook; Manisha Menon; Dheeraj Soni; Simone Schüller; Karthik Siram; Etsuro Nanishi; Hélène G Bazin; David J Burkhart; Ofer Levy; Jay T Evans
Journal:  Sci Rep       Date:  2022-10-18       Impact factor: 4.996

Review 4.  The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.

Authors:  Vega Masignani; Mariagrazia Pizza; E Richard Moxon
Journal:  Front Immunol       Date:  2019-04-16       Impact factor: 7.561

Review 5.  Safety of Maternal Immunization Against Pertussis: A Systematic Review.

Authors:  Caroline D'Heilly; Charlotte Switzer; Denis Macina
Journal:  Infect Dis Ther       Date:  2019-09-17

Review 6.  Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.

Authors:  Nikolai Petrovsky
Journal:  Drug Saf       Date:  2015-11       Impact factor: 5.606

7.  Adjuvant-induced Human Monocyte Secretome Profiles Reveal Adjuvant- and Age-specific Protein Signatures.

Authors:  Djin-Ye Oh; David J Dowling; Saima Ahmed; Hyungwon Choi; Spencer Brightman; Ilana Bergelson; Sebastian T Berger; John F Sauld; Matthew Pettengill; Alvin T Kho; Henry J Pollack; Hanno Steen; Ofer Levy
Journal:  Mol Cell Proteomics       Date:  2016-03-01       Impact factor: 5.911

8.  Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics.

Authors:  Vinayaka Kotraiah; Timothy W Phares; Cecille D Browne; James Pannucci; Marc Mansour; Amy R Noe; Kenneth D Tucker; Jayne M Christen; Charles Reed; Alecia MacKay; Genevieve M Weir; Rajkannan Rajagopalan; Marianne M Stanford; Chun-Shiang Chung; Alfred Ayala; Jing Huang; Moriya Tsuji; Gabriel M Gutierrez
Journal:  Front Immunol       Date:  2020-03-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.